MX2018011392A - Composiciones canabinoides y basadas en canabis y metodos para el tratamiento de condiciones inflamatorias del tracto gastrointestinal. - Google Patents

Composiciones canabinoides y basadas en canabis y metodos para el tratamiento de condiciones inflamatorias del tracto gastrointestinal.

Info

Publication number
MX2018011392A
MX2018011392A MX2018011392A MX2018011392A MX2018011392A MX 2018011392 A MX2018011392 A MX 2018011392A MX 2018011392 A MX2018011392 A MX 2018011392A MX 2018011392 A MX2018011392 A MX 2018011392A MX 2018011392 A MX2018011392 A MX 2018011392A
Authority
MX
Mexico
Prior art keywords
methods
treating inflammatory
canabis
canabinoid
gastrointestinal tract
Prior art date
Application number
MX2018011392A
Other languages
English (en)
Spanish (es)
Inventor
Bar-Lev Schleider Lihi
Original Assignee
To Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by To Pharmaceuticals Llc filed Critical To Pharmaceuticals Llc
Publication of MX2018011392A publication Critical patent/MX2018011392A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2018011392A 2016-03-28 2017-03-28 Composiciones canabinoides y basadas en canabis y metodos para el tratamiento de condiciones inflamatorias del tracto gastrointestinal. MX2018011392A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662313882P 2016-03-28 2016-03-28
PCT/IL2017/050388 WO2017168422A1 (en) 2016-03-28 2017-03-28 Cannabionid and cannabis-based compositions and methods for the treatment of inflammatory conditions of the gastrointestinal tract

Publications (1)

Publication Number Publication Date
MX2018011392A true MX2018011392A (es) 2019-07-08

Family

ID=58579244

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011392A MX2018011392A (es) 2016-03-28 2017-03-28 Composiciones canabinoides y basadas en canabis y metodos para el tratamiento de condiciones inflamatorias del tracto gastrointestinal.

Country Status (11)

Country Link
US (2) US20190091198A1 (https=)
EP (1) EP3436001A1 (https=)
JP (1) JP2019510060A (https=)
KR (1) KR20180130544A (https=)
AU (1) AU2017242161A1 (https=)
BR (1) BR112018069860A2 (https=)
CA (1) CA3018951A1 (https=)
IL (1) IL261799A (https=)
MX (1) MX2018011392A (https=)
WO (1) WO2017168422A1 (https=)
ZA (1) ZA201807098B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019130215A1 (en) * 2017-12-27 2019-07-04 To Pharmaceuticals Llc Cannabis compositions for the treatment of inflammatory skin disorders
CA3087269A1 (en) 2018-01-10 2019-07-18 Brightseed, Inc. Method for modulating metabolism
WO2019159185A1 (en) * 2018-02-19 2019-08-22 To Pharmaceuticals Llc Compositions and methods for the treatment of protein energy wasting
CA3113724A1 (en) * 2018-09-28 2020-04-02 Visceral Therapeutics Inc. Pharmaceutically active cannabis-based compositions and methods of use for treating gastrointestinal conditions
WO2020123383A1 (en) * 2018-12-10 2020-06-18 Natural Extraction Systems, LLC Compositions with novel cannabinoid and terpene profiles
AU2019412825A1 (en) * 2018-12-27 2021-08-12 Buzzelet Development And Technologies Ltd. Herbal preparation-enriched cannabinoid composition and method of treatment
US10993928B2 (en) 2019-04-26 2021-05-04 Natural Extraction Systems, LLC Compositions comprising non-crystalline forms of cannabidiol
WO2020219829A1 (en) * 2019-04-26 2020-10-29 Natural Extraction Systems, LLC Compositions comprising non-crystalline forms of cannabidiol
CN114929033A (zh) * 2019-07-29 2022-08-19 布莱特西德公司 改善消化健康的方法
WO2021113261A1 (en) * 2019-12-02 2021-06-10 Natural Extraction Systems, LLC Compositions comprising novel cannabinoid and terpene profiles
BR112022010335A2 (pt) * 2020-01-08 2022-08-16 Nestle Sa Composição sólida oral de óleo canabinoide para o tratamento de distúrbios gastrointestinais
WO2021248207A1 (en) * 2020-06-12 2021-12-16 Zelira Therapeutics Operations Pty Ltd Composition and method for treating chronic pain
GB202101732D0 (en) * 2021-02-08 2021-03-24 Tts Pharma Ltd A cannabinoid mixture
AU2022324615A1 (en) 2021-08-04 2024-02-15 Demeetra Agbio, Inc. Cannabinoid derivatives and their use
WO2023060323A1 (en) * 2021-10-15 2023-04-20 Bod Science Limited Terpene-containing formulations and use thereof
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2450741A (en) * 2007-07-05 2009-01-07 Gw Pharma Ltd Cannabinoid containing plant extracts in the treatment of inflammatory bowel disease
US20140245495A1 (en) 2013-02-25 2014-08-28 Ytzchak Cohen Cannabis plant named midnight
US20140259228A1 (en) 2013-02-25 2014-09-11 Ytzchak Cohen Cannabis plant named 'avidekel'
US20140245494A1 (en) 2013-02-25 2014-08-28 Ytzchak Cohen Cannabis plant named erez

Also Published As

Publication number Publication date
AU2017242161A1 (en) 2018-11-01
US20190091198A1 (en) 2019-03-28
US20200397743A1 (en) 2020-12-24
JP2019510060A (ja) 2019-04-11
EP3436001A1 (en) 2019-02-06
CA3018951A1 (en) 2017-10-05
BR112018069860A2 (pt) 2020-11-03
WO2017168422A1 (en) 2017-10-05
ZA201807098B (en) 2020-01-29
IL261799A (en) 2018-10-31
KR20180130544A (ko) 2018-12-07

Similar Documents

Publication Publication Date Title
MX2018011392A (es) Composiciones canabinoides y basadas en canabis y metodos para el tratamiento de condiciones inflamatorias del tracto gastrointestinal.
CL2021000343A1 (es) Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128)
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
CL2018000150A1 (es) Compuestos útiles como inmunomoduladores (divisional de solicitud 201600508)
CL2017000850A1 (es) Uso de l.reuteri para la recuperación de la disbiosis de microbiota en los primeros años de vida.
MX2017006302A (es) Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
PH12017500941A1 (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
BR112018013011A2 (pt) composições de alimento para animais de estimação
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
MX2017014488A (es) Composiciones para transplante de la flora fecal y metodos para elaborarlos y utilizarlos y dispositivos para suministrarlos.
EA201791451A1 (ru) 5-[(пиперазин-1-ил)-3-оксо-пропил]-имидазолидин-2,4-дионовые производные в качестве ингибиторов adamts для лечения остеоартрита
MY192717A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
PH12021551455A1 (en) Jak1 pathway inhibitors for the treatment of gastrointestinal disease
EA201692091A1 (ru) Хиноксалиновые соединения и их применение
CL2018001621A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)
EP3294761A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF UROPATHOGEN E. COLI
MX385762B (es) Métodos para el control transcripcional objetivo en regiones del super mejorador.
BR112017014107A2 (pt) composição nutricional útil no tratamento de pacientes com ibd
EA201991301A1 (ru) Урогенитальная композиция для медицинского устройства на основе подходящих биохимических композиций для стабилизации кислотности и редокс-состояния вагинальной жидкости
MX381944B (es) Lixisenatida para usarse en el tratamiento de diabetes mellitus de tipo 2 en pacientes pediàtricos.
MX2017002385A (es) Metodos y reactivos para la prevencion y/o el tratamiento de infecciones.
UY36373A (es) Compuestos para usarse en el tratamiento antihelmíntico
UY36196A (es) Compuestos para usar en el tratamiento antihelmíntico
EA201792669A1 (ru) Igfbp3 и его применение
MX2020014206A (es) Derivados del 1,3,5-tris(6-metilpiridin-2-iloxi)benceno y compuestos relacionados como ligandos del nlrx1 para el tratamiento de enfermedades inflamatorias.